Categories: News

Employee Elected Director to step down from the board of Zealand Pharma A/S

Company announcement No. 51 / 2021

Employee Elected Director to step down from the board of Zealand Pharma A/S

Copenhagen, DK, August 13, 2021 Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078). Gertrude Koefoed Rasmussen an employee elected member of the Board of Zealand will step down from her position on the board effective as of 31 August 2021 and leave Zealand to take up an offer of employment at another company.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery, development and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late-stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Zealand Pharma Investor Relations
Claudia Styslinger
Argot Partners
investors@zealandpharma.com 

Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com 

Staff

Recent Posts

Health Union Launches New Online Community, ATTR-Amyloidosis.net

New Digital Health Community Delivers Rare Disease Resources and Peer Support for ATTR Amyloidosis Patients…

1 hour ago

PR Daily Honors MediaSource as one of 2025’s Top Public Relations Agencies

Industry-leading health care firm closes 2025 with multiple Agency of the Year honors COLUMBUS, Ohio,…

1 hour ago

Cadwell and Medical Informatics Corp. Announce Partnership to Bring Neurodiagnostic Data into Clinical Intelligence Ecosystem

KENNEWICK, Wash. and HOUSTON, Dec. 11, 2025 /PRNewswire/ -- Cadwell, a global leader in neurodiagnostic…

7 hours ago

Thatch and ADP Simplify Small Business Healthcare with Seamless ICHRA Integration via RUN Powered by ADP

New embedded solution empowers more than 900,000 small businesses to offer flexible, affordable health coverage directly…

7 hours ago

Suvoda IRT named a Leader in Everest Group’s RTSM PEAK Matrix®

CONSHOHOCKEN, Pa., Dec. 11, 2025 /PRNewswire/ -- Suvoda, a global clinical trial technology company, today announced…

7 hours ago